Setting a New Scene in the Treatment of Relapsed/Refractory Multiple Myeloma

Speaker: Antonio Palumbo

A. Palumbo emphasizes that novel monoclonal antibodies will transform care in patients with multiple myeloma in the way that R-CHOP regimen did in the field of lymphoma. The current regimens have already doubled the survival in multiple myeloma and there is a lot of expectations for further improvement with new agents. He elaborates the results from the ELOQUENT-2 study of lenalidomide/ dexamethasone with or without elotuzumab, ENDEAVOR study of carfilzomib/ dexamethasone vs bortezomib/ dexamethasone, and daratumumab monotherapy.

Discussion Points

  • ELOQUENT-2: Lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma (ASCO 2015 abstract #8508)
  • ENDEAVOR: Carfilzomib and dexamethasone vs bortezomib and dexamethasone in relapsed multiple myeloma (ASCO 2015 abstract #8509)
  • Daratumumab monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (ASCO 2015 abstract #LBA8512)